Corporate Action2 Min Read InvestyWise NewsonJanuary 31, 2026 Sun Pharma Q3FY26 Revenue Up 15.1%, Interim Dividend Declared Sun Pharmaceutical Industries reported a 15.1% YoY increase in revenue to ₹154,691 million for Q3FY26. Net profit rose by 16.0% to ₹33,688…
Board Meeting1 Min Read InvestyWise NewsonJanuary 31, 2026 Birla Corporation Board Approves Q3 Results, Extends Key Personnel Terms Birla Corporation’s Board approved the unaudited financial results for Q3 FY26, with standalone revenue at ₹1,197.94 Crores and a profit…
Company Results1 Min Read InvestyWise NewsonJanuary 31, 2026 Sun Pharma Reports Q3FY26 Results, Interim Dividend Declared Sun Pharmaceutical Industries Limited announced its Q3FY26 results with sales up by 15.1% YoY to ₹154,691 million. Net profit increased by…
Company Update2 Min Read InvestyWise NewsonJanuary 31, 2026 Clean Science Q3 FY26 Results, Hydroquinone Production Begins Clean Science and Technology Limited (CSTL) announced its Q3 FY26 results, showcasing resilient EBITDA margins amid challenging market…
Company Results1 Min Read InvestyWise NewsonJanuary 31, 2026 Clean Science Declares Interim Dividend and Approves Q3 Results Clean Science and Technology Limited announced the approval of its unaudited standalone and consolidated financial results for Q3 FY26. The…
Board Meeting1 Min Read InvestyWise NewsonJanuary 31, 2026 Clean Science and Technology Declares Interim Dividend; Q3 Results Announced Clean Science and Technology has announced its Q3 results and declared an interim dividend of ₹2/- per equity share. The company’s…
Company Update1 Min Read InvestyWise NewsonJanuary 31, 2026 MOIL Limited JV Approval Received from Ministry of Steel MOIL Limited has received approval from the Ministry of Steel for a Joint Venture (JV) agreement with Madhya Pradesh State Mining Corporation…
Board Meeting1 Min Read InvestyWise NewsonJanuary 31, 2026 Vinati Organics Reports Q3 Results, Dividend & Policy Revisions Vinati Organics Limited announced its unaudited financial results for the quarter and nine months ended December 31, 2025. The company’s…
Company Update1 Min Read InvestyWise NewsonJanuary 31, 2026 AstraZeneca Receives Approval for Durvalumab (Imfinzi) for Gastric Cancer Treatment AstraZeneca Pharma India has received approval to import, sell, and distribute Durvalumab Solution for Infusion (120 mg/2.4 mL and 500 mg/10…
Board Meeting1 Min Read InvestyWise NewsonJanuary 31, 2026 AstraZeneca Board Meeting Scheduled to Approve Unaudited Financial Results AstraZeneca Pharma India Ltd. has announced a meeting of its Board of Directors on February 11, 2026, to consider and approve the unaudited…